Temozolomide (TMZ), an effective drug for glioma, has been shown to control invasion and proliferation of malignant glioma by inhibiting AQP4 expression secondary to the activation of p38 signaling in glioma cell lines (Chen et al., 2017[11]). Here, AQP4 is linked to central nervous system cancer.